 Home > Biochemistry News > Biotechnology News > The first! Takeda's antiviral therapy Livtencity receives FDA approval

The first! Takeda's antiviral therapy Livtencity receives FDA approval

 Last Update: 2021-12-01
 Source: Internet
 Author: User

Tags

protein group

post hyperpigmentation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, the U.

CMV is a beta herpes virus that can infect humans and is one of the most common infections in transplant patients.

Livtencity blocks the replication of the virus by inhibiting the pUL97 protein kinase of the CMV virus

The efficacy and safety of Livtencity are supported by an open-label, phase 3 clinical trial with activity control

Reference materials:

[1] FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.